Amneal Pharmaceuticals (AMRX) Rating Reiterated by Canaccord Genuity
Canaccord Genuity reissued their hold rating on shares of Amneal Pharmaceuticals (NYSE:AMRX) in a research report released on Tuesday. Canaccord Genuity currently has a $21.00 price target on the stock.
Several other research firms have also commented on AMRX. B. Riley raised their price objective on Amneal Pharmaceuticals from $26.00 to $28.00 and gave the company a buy rating in a research report on Wednesday, August 22nd. Royal Bank of Canada raised Amneal Pharmaceuticals from a sector perform rating to an outperform rating in a research report on Monday, August 13th. BMO Capital Markets raised their price objective on Amneal Pharmaceuticals from $19.00 to $20.00 and gave the company a market perform rating in a research report on Friday, August 10th. Cantor Fitzgerald reissued a buy rating and issued a $35.00 price objective on shares of Amneal Pharmaceuticals in a research report on Thursday, August 9th. Finally, Zacks Investment Research raised Amneal Pharmaceuticals from a strong sell rating to a hold rating in a research report on Wednesday, May 30th. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $23.57.
NYSE:AMRX opened at $23.50 on Tuesday. The company has a debt-to-equity ratio of 2.85, a quick ratio of 1.25 and a current ratio of 2.01. Amneal Pharmaceuticals has a 12 month low of $13.47 and a 12 month high of $25.70. The stock has a market capitalization of $6.89 billion, a price-to-earnings ratio of 37.30, a P/E/G ratio of 1.02 and a beta of 1.38.
In other news, CFO Bryan M. Reasons sold 11,698 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $23.65, for a total transaction of $276,657.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nikita Shah sold 50,000 shares of the firm’s stock in a transaction dated Tuesday, August 21st. The shares were sold at an average price of $23.46, for a total value of $1,173,000.00. The disclosure for this sale can be found here. 3.20% of the stock is owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at about $120,000. Neuburgh Advisers LLC acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at about $123,000. Great West Life Assurance Co. Can acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at about $130,000. Sei Investments Co. acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at about $139,000. Finally, Riverhead Capital Management LLC acquired a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at about $141,000. Institutional investors own 32.39% of the company’s stock.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.
Featured Story: Return on Investment (ROI) Defined, Explained
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.